RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment
Sign Up to like & getrecommendations! Published in 2017 at "Virchows Archiv"
DOI: 10.1007/s00428-017-2291-z
Abstract: Wild-type status of KRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined before treatment of metastatic colorectal cancer (mCRC) patients with EGFR-targeting agents. There is a large variation… read more here.
Keywords: ras testing; colorectal cancer; quality assessment; european laboratories ... See more keywords
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx417
Abstract: Background Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information is available on the predictive role of liquid biopsy RAS testing in patients treated with first-line… read more here.
Keywords: plasma; tissue; liquid biopsy; ras testing ... See more keywords
Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
Sign Up to like & getrecommendations! Published in 2017 at "BMC Cancer"
DOI: 10.1186/s12885-017-3740-4
Abstract: BackgroundIn Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies – a physician survey and a medical records review (MRR) – were conducted to evaluate… read more here.
Keywords: physician survey; metastatic colorectal; cancer; ras testing ... See more keywords